XERS XP-8121 targets $1–3B peak sales by 2030 launch
XERS said XP-8121, a once-weekly injectable levothyroxine, aims for $1–3B peak sales, targeting 3–5 million hypothyroid patients inadequately controlled on oral therapy. An FDA-aligned pivotal trial is set to support approval and launch by 2030.
XP-8121, a once-weekly injectable levothyroxine, is aimed at 3—5 million hypothyroid patients who are not adequately controlled on oral therapy. The program includes a robust clinical package, and a FDA-aligned pivotal trial is planned to support approval and launch by 2030. Peak sales are projected at $1—3 billion. The strategy is to leverage strong physi…